The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-25), Spero Therapeutics's share price is $1.42. Spero Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $2.02. Hence, Spero Therapeutics's PB Ratio of today is 0.70.
Good Sign:
Spero Therapeutics Inc stock PB Ratio (=0.71) is close to 1-year low of 0.68
The historical rank and industry rank for Spero Therapeutics's PB Ratio or its related term are showing as below:
SPRO'
s PB Ratio Range Over the Past 10 Years
Min: 0.49 Med: 2.12 Max: 6.3
Current: 0.7
During the past 9 years, Spero Therapeutics's highest PB Ratio was 6.30. The lowest was 0.49. And the median was 2.12.
SPRO's PB Ratio is ranked better than 86.65% of 1311
companies
in the Biotechnology industry
Industry Median: 2.37
vs SPRO: 0.70
During the past 12 months, Spero Therapeutics's average Book Value Per Share Growth Rate was 39.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -23.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -23.70% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Spero Therapeutics was -8.50% per year. The lowest was -28.00% per year. And the median was -24.75% per year.
Back to Basics: PB Ratio
Spero Therapeutics PB Ratio Historical Data
The historical data trend for Spero Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Spero Therapeutics's PB Ratio
For the Biotechnology subindustry, Spero Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spero Therapeutics's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spero Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Spero Therapeutics's PB Ratio falls into.
Spero Therapeutics PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Spero Therapeutics's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Spero Therapeutics (NAS:SPRO) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Spero Therapeutics PB Ratio Related Terms
Thank you for viewing the detailed overview of Spero Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Spero Therapeutics (Spero Therapeutics) Business Description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SPRO has been successfully added to your 